2seventy bio, Inc.
TSVTDelisted May 13, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001860782
2seventy bio, Inc. was delisted on May 13, 2025; its insiders filed their last Form 4 on May 15, 2025; 140 institutions reported holding it in 13F filings for Q1 2025, worth $234.5M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by 2seventy bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for 2seventy bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Casdin Partners GP, LLC | Director | 0Indirect | May 15, 2025 | 0 |
| Casdin Capital, LLC | Director | 0Indirect | May 15, 2025 | 0 |
| Casdin Eli | Director | 0Indirect | May 15, 2025 | 0 |
| Casdin Partners Master Fund, L.P. | Director | 0Indirect | May 15, 2025 | 0 |
| Baird William D III | President and CEO | 0 | May 15, 2025 | 0 |
| Leschly Nick | Director | 0Indirect | May 15, 2025 | 0 |
| Glickman Sarah JS | Director | 0 | May 15, 2025 | 0 |
| Torres Denice | Director | 0 | May 15, 2025 | 0 |
| Newton Charles W. | Director | 0 | May 15, 2025 | 0 |
| Wei Lin | Director | 0 | May 15, 2025 | 0 |
| Maus Marcela V. | Director | 0 | May 15, 2025 | 0 |
| Snow Jessica | Chief Operating Officer | 0 | May 15, 2025 | 0 |
| Eatwell Victoria | Chief Financial Officer | 0 | May 15, 2025 | 0 |
| Kynam Capital Management, LP | 10% Owner | 0Indirect | Mar 13, 2025 | 0 |
| Kynam Capital Management GP, LLC | 10% Owner | 0Indirect | Mar 13, 2025 | 0 |
| Kynam Global Healthcare Master Fund, LP | 10% Owner | 0Indirect | Mar 13, 2025 | 0 |
| Kynam Fund GP, LLC | 10% Owner | 0Indirect | Mar 13, 2025 | 0 |
| Tang Yue | 10% Owner | 0Indirect | Mar 13, 2025 | 0 |
| Gregory Philip D | Chief Scientific Officer | 310,280 | Jan 9, 2024 | 0 |
| Lynch Daniel | Director | 21,053 | Jun 15, 2023 | 0 |
| Ibrahim Ramy | Director | 19,050 | Jun 15, 2023 | 0 |
| Heffron Nicola | Chief Operating Officer | 89,182 | Feb 9, 2023 | 0 |
| Sellers William R. | Director | 3,202 | Nov 16, 2021 | 0 |
| bluebird bio, Inc. | 10% Owner | 0 | Nov 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 11, 2023 (view filing) | Jan 9 | 2 days | Leschly NickPresident and CEO | SSale | −2.98K | $10.33 | −$30.8K | −0.5%543.0K after | |
| Dec 6, 2022 (view filing) | Dec 5 | 1 day | Heffron NicolaChief Operating Officer | SSale | −272 | $15.43 | −$4.20K | −0.3%90.0K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Heffron NicolaChief Operating Officer | SSale | −7.70K | $13.97 | −$107.5K | −7.9%90.2K after | |
| Aug 8, 2022 (view filing) | Aug 5 | 3 days | Baird William D IIIChief Financial Officer | SSale | −4.15K | $16.23 | −$67.4K | −4.8%83.1K after | |
| Aug 8, 2022 (view filing) | Aug 5 | 3 days | Gregory Philip DChief Scientific Officer | SSale | −2.41K | $16.23 | −$39.1K | −2.3%104.4K after | |
| Aug 8, 2022 (view filing) | Aug 5 | 3 days | Leschly NickPresident and CEO | SSale | −5.50K | $16.23 | −$89.2K | −1.0%546.0K after | |
| Jul 19, 2022 (view filing) | Jul 15 | 4 days | Baird William D IIIChief Financial Officer | SSale | −4.08K | $13.81 | −$56.3K | −4.5%87.2K after | |
| Jul 19, 2022 (view filing) | Jul 15 | 4 days | Gregory Philip DChief Scientific Officer | SSale | −2.37K | $13.81 | −$32.7K | −2.2%106.8K after | |
| Jul 19, 2022 (view filing) | Jul 15 | 4 days | Leschly NickPresident and CEO | SSale | −5.40K | $13.81 | −$74.6K | −1.0%551.5K after | |
| Mar 22, 2022 (view filing) | Mar 17 | 5 days | Leschly NickPresident and CEO | PPurchase | +368.9K | $12.20 | +$4.50M | +196.2%556.9K after | Amended |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Baird William D IIIChief Financial Officer | SSale | −427 | $14.78 | −$6.31K | −0.7%57.6K after | |
| Feb 8, 2022 (view filing) | Feb 4-7 | 4 days | Heffron NicolaChief Operating Officer | SSale | −2.10K | $15.88 | −$33.4K | −3.7%55.4K after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 7 | 4 days | Baird William D IIIChief Financial Officer | SSale | −896 | $23.91 | −$21.4K | −1.5%58.0K after | |
| Jan 11, 2022 (view filing) | Jan 7 | 4 days | Gregory Philip DChief Scientific Officer | SSale | −1.45K | $23.91 | −$34.7K | −2.3%61.7K after | |
| Jan 11, 2022 (view filing) | Jan 7 | 4 days | Leschly NickPresident and CEO | SSale | −3.27K | $23.91 | −$78.2K | −1.7%188.0K after | |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Heffron NicolaChief Operating Officer | SSale | −257 | $31.06 | −$7.98K | −0.4%57.5K after |